Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

BRAF serine-threonine kinase (BRAF) inhibitors & Melanoma (cutaneous) (BRAF m)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

When tumors are treated with BRAF serine-threonine kinase (BRAF) inhibitors monotherapy, they often develop resistance within six months.
Dugan et al. 2024 Cancer Manag Res 16: 933-939

…

Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma
Tarhini et al. 2019
Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation-Positive Melanoma: Patient Selection and Perspectives
Dugan et al. 2024 Cancer Manag Res 16: 933-939
Review
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Chapman et al., 2011 N Engl J Med. 364(26): 2507-16
Inside Life of Melanoma Cell Signaling, Molecular Insights, and Therapeutic Targets
Sosman & Margolin 2009
Review

7/1/2026